Resistant ovary syndrome and oocyte maturation in a test tube


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Resistant ovarian syndrome (ROS) is a rare endocrine disease characterized by hypergonadotropic hypogonadism, primary or secondary amenorrhea, generally a normal number of ovarian antral follicles, resistance to endogenous and exogenous gonadotropins, a normal set of chromosomes, and correctly developed secondary sexual characteristics. Patients with this syndrome are included in the third group of the WHO classification of chronic anovulation. Infertility in these patients may be overcome with both donor programs and their own oocytes in assisted reproductive technology programs using in vitro maturation (IVM). This review presents the global experience with IVM technology leading to the birth of healthy babies in women with ROS.

全文:

受限制的访问

作者简介

Pavel Yakovlev

Next Generation Clinic

Email: iakovlevpp@gmail.com
PhD, obstetrician-gynecologist

Rostislav Kornilov

Next Generation Clinic

medical consultant

Marina Pavlova

Next Generation Clinic

Head of the embryological laboratory

Nikolay Kornilov

Next Generation Clinic

medical director, obstetrician-gynecologist

参考

  1. Jones G.S., De Moraes-Ruehsen M. A new syndrome of amenorrhae in association with hypergonadotropism and apparently normal ovarian follicular apparatus. Am. J. Obstet. Gynecol. 1969; 104(4): 597-600.
  2. Khor S., Lyu Q., Kuang Y., Lu X. Novel FSHR variants causing female resistant ovary syndrome. Mol. Genet. Genomic Med. 2019; 8(2): e1082. https://dx.doi. org/10.1002/mgg3.1082.
  3. Galvao A, Segers I., Smitz J., Tournaye H., De Vos M. In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation. J. Assist. Reprod. Genet. 2018; 35(12): 2161-71. https://dx.doi.org/10.1007/s10815-018-1317-z.
  4. Huhtaniemi I., Alevizaki M. Gonadotrophin resistance. Best Pract. Res. Clin. Endocrinol. Metab. 2006; 20(4): 561-76. https://dx.doi. org/10.1016/j. beem.2006.09.003.
  5. Flageole C., Toufaily C., Bernard D.J., Ates S., Blais V., Chenier S. et al. Successful in vitro maturation of oocytes in a woman with gonadotropin-resistant ovary syndrome associated with a novel combination of FSH receptor gene variants: a case report. J. Assist. Reprod. Genet. 2019; 36(3): 425-32. https://dx.doi. org/10.1007/s10815-018-1394-z.
  6. Desai S.S., Roy B.S., Mahale S.D. Mutations and polymorphisms in FSH receptor: functional implications in human reproduction. Reprod. Camb. Engl. 2013; 146(6): R235-48. https://dx.doi.org/10.1530/REP-13-0351.
  7. Rogenhofer N., Pavlik R., Jeschke U., Wypior G., Ochsenkuhn R., Thaler C.J. Effective ovarian stimulation in a patient with resistant ovary syndrome and antigonadotrophin antibodies. Am. J. Reprod. Immunol. 2015; 73(2): 185-91. https://dx.doi.org/10.1111/aji.12306.
  8. Huhtaniemi I.T., Themmen A.P. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine. 2005; 26(3): 207-17. https://dx.doi. org/10.1385/END0:26:3:207.
  9. Themmen A.P.N., Huhtaniemi I.T. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr. Rev. 2000; 21(5): 551-83. https://dx.doi.org/10.1210/ edrv.21.5.0409.
  10. Haller-Kikkatalo K., Salumets A., Uibo R. Review on autoimmune reactions in female infertility: antibodies to follicle stimulating hormone. Clin. Dev. Immunol. 2012; 2012: 762541. https://dx.doi.org/10.1155/2012/762541.
  11. NICE Guideline “Fertility problems: assessment and treatment”. September 2017.
  12. ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum. Reprod. Update. 2012; 18(5): 586-99. https://dx.doi.org/10.1093/humupd/dms019.
  13. Grynberg M., Peltoketo H., Christin-Maitre S., Poulain M., Bouchard P., Fanchin R. First birth achieved after in vitro maturation of oocytes from a woman endowed with multiple antral follicles unresponsive to follicle-stimulating hormone. J. Clin. Endocrinol. Metab. 2013; 98(11): 4493-8. https://dx.doi. org/10.1210/jc.2013-1967.
  14. De Vos M., Smitz J., Thompson J.G., Gilchrist R.B. The definition of IVM is clear - variations need defining. Hum. Reprod. 2016; 31(11): 2411-5. https:// dx.doi.org/10.1093/humrep/dew208.
  15. Edwards R.G. Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and human ovarian oocytes. Nature. 1965; 208(5008): 349-51.
  16. Chian R.C., Buckett W.M., Too L.L., Tan S.L. Pregnancies resulting from in vitro matured oocytes retrieved from patients with polycystic ovary syndrome after priming with human chorionic gonadotropin. Fertil. Steril. 1999; 72(4): 639-42. https://dx.doi.org/10.1016/ S0015-0282(99)00323-4.
  17. Dahan M.H., Tan S.L., Chung J., Son W.Y. Clinical definition paper on in vitro maturation of human oocytes. Hum. Reprod. 2016; 31(7): 1383-6. https:// dx.doi.org/10.1093/humrep/dew109.
  18. Fadini R., Coticchio G., Brambillasca F., Mignini Renzini M., Novara P.V., Brigante C. et al. Clinical outcomes from mature oocytes derived from preovulatory and antral follicles: reflections on follicle physiology and oocyte competence. J. Assist. Reprod. Genet. 2015; 32(2): 255-61. https://dx.doi.org/10.1007/s10815-014-0386-x.
  19. Li Y., Pan P., Yuan P., Qiu Q., Yang D. Successful live birth in a woman with resistant ovary syndrome following in vitro maturation of oocytes. J. Ovarian Res. 2016; 9(1): 54. https://dx.doi.org/10.1186/s13048-016-0263-6.
  20. Yang Z.Y., Chian R.C. Development of in vitro maturation techniques for clinical applications. Fertil. Steril. 2017; 108(4): 577-84. https://dx.doi.org/ 10.1016/ j.fertnstert.2017.08.020.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2020